Table 3. Improvement of obesity-related comorbidities in the course of the 52-week-lifestyle intervention program.
| n | T0[%] | T1/TEnd [%] | T2 [%] | |
|---|---|---|---|---|
| Metabolic syndrome (IDF criteria) | ||||
| PP (n (%)) | 3893 | 54% | 19%*** | 23%*** |
| ITT (n (%)) | 6759 | 57% | 30%*** | |
| Hypertriglyceridemia | ||||
| PP (n (%)) | 3929 | 24% | 11%*** | 14%*** |
| ITT (n (%)) | 6734 | 25% | 17%*** | |
| Hypercholesterolemia | ||||
| PP (n (%)) | 3026 | 17% | 13%*** | 14% |
| ITT (n (%)) | 5380 | 14% | 12%** | |
| Fatty liver diseasea | ||||
| PP (n (%)) | 3504 | 17% | 5%** | 5% |
| ITT (n (%)) | 6102 | 13% | 9%*** | |
| Diabetesa | ||||
| PP (n (%)) | 3814 | 11% | 3%*** | 4%*** |
| ITT (n (%)) | 6616 | 11% | 6%*** | |
| Renal failurea | ||||
| PP (n (%)) | 3940 | 7% | 7% | 7% |
| ITT (n (%)) | 6774 | 6% | 8% | |
Abbreviations: IDF, International Diabetes Federation; ITT, intention-to-treat; PP, per protocol analysis.**P<0.01.
***P<0.001 compared with T0 values at T1/TEnd, or compared with T1 values at T2.
a
For definition of disease, see Materials and methods.